Guidelines from the American Association of Clinical Endocrinology recommend considering glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in addition to metformin for patients who have not reached their glycemic target. Initial combination therapy may also be considered in patients with type 2 diabetes presenting with A1c levels 1.5%-2.0% above target. Research has shown that GLP-1 RAs are the most effective non-insulin agent in reducing hemoglobin A1c in patients with uncontrolled type 2 diabetes. Incretin-based therapy can also be considered in patients with contraindications to metformin, such as in those with renal dysfunction.
Learn more about pharmacologic therapy for type 2 diabetes.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori, Anne L. Peters. Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy - Medscape - Apr 28, 2023.